Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the presence of the A-AA allele at the PSA promoter region is associated with less aggressive forms of breast cancer and could be looked on as a favorable prognostic factor.
|
12168876 |
2002 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era.
|
18646000 |
2008 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Current smoking (RR=0.86, 0.83-0.90), non-participation in breast cancer screening (female) or PSA testing (male) (RR=0.84, 0.81-0.86), poor self-reported health (RR=0.89, 0.86-0.91), lower levels of education (RR=0.91, 0.90-0.93), and not speaking English at home (RR=0.88, 0.85-0.91) were associated with reduced ever-uptake of screening within the NBCSP and of any CRC screening.
|
29109015 |
2018 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no significant association between the PSA gene polymorphism and breast cancer risk, nor was there significant gene-gene interaction.
|
16365023 |
2005 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Retrospective inception cohort study of male Veterans aged 40 to 89 years with a laboratory-defined low testosterone measurement from 2002 to 2011 and recent prostate specific antigen (PSA) testing; excluding those with recent testosterone treatment, prostate or breast cancer, high PSA or prior prostate biopsy.
|
29933385 |
2018 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previous studies have shown that the coding region of the PSA gene is not a target for mutations in prostate cancer and breast cancer.
|
11185746 |
2000 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter.
|
10942096 |
2000 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Differences were detected in the completion of screening tests for colorectal cancer (p < 0.001), breast cancer (p = 0.023), cervical cancer (p = 0.006), and prostate-specific antigen determination (p < 0.001) in relation to the participants' academic profiles.
|
31848937 |
2019 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, we identified two novel polymorphisms in the PSA promoter ARE2 region in breast cancer.
|
11299734 |
2001 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical significance of serum PSA in breast cancer patients.
|
31664946 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
One of these genes encodes for prostate-specific antigen (PSA), a favorable prognostic factor in breast cancer.
|
10794483 |
2000 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
( n = 73); 2) Angina: treatment options ( n = 88); 3) Breast cancer: surgical options ( n = 265); 4) Prostate Specific Antigen (PSA) test: yes or no?
|
29078054 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As IGFs, IGFBPs and PSA are all present in breast cancer, possible associations among these proteins were speculated.
|
8883411 |
1996 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, BM samples from 63 patients with prostate cancer (n = 53) or breast cancer (n = 10) were analyzed by RT-PCR with primers specific for prostate-specific antigen (PSA) mRNA.
|
9215843 |
1997 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently we have demonstrated prostate-specific antigen (PSA) expression in breast tumours to be suggestive of favourable prognosis, but quantitative relationships between PSA and p53, and between these and other prognostic factors in breast cancer, have not been investigated.
|
7545416 |
1995 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Like KLK2 and KLK3, the KLK5 gene is regulated by steroid hormones in the BT-474 breast cancer cell line.
|
11948967 |
2002 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extracts from 952 primary breast carcinomas were assayed for PSA and p53 by quantitative enzyme-linked immunosorbent assays (ELISAs) developed by the authors.
|
10507775 |
1999 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results obtained indicated PSA species common to BCa, PCa, and BPH at 12-13 kDa, 17-19 kDa and 21-24 kDa.
|
30581329 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We were able to detect the amplified PSA fragment in 18 of 78 women with breast cancer; 7 of the 18 women with the PSA fragment had localised, small, node-negative tumours, both oestrogen receptor (ER) positive and ER negative.
|
8826851 |
1996 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-specific antigen (PSA) in prostate cancer (PC) screening among breast cancer, early-onset gene (BRCA) mutation carriers.
|
25746941 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To account for unmeasured factors, the correlation between changes in PSA screening over time and changes in screening for colorectal and breast cancer were assessed.All analyses were conducted in 2016.
|
29056579 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum PSA could be a useful biomarker for the diagnosis of breast cancer, and a biomarker for the differential diagnosis of breast cancer from benign breast tumors.
|
30024607 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pilot study was performed using both EST and SAGE vNorthern to analyze the expression of a panel of known genes, including high abundance genes beta-actin and G3PDH, low abundance genes BRCA1 and p53, tissue-specific genes CEA and PSA and two breast cancer-related genes Her2/neu and MUC1.
|
15647832 |
2005 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Use of CRC screening tests was significantly lower than mammography for breast cancer detection in women (20 vs. 82%, P<0.001) and use of serum prostate-specific antigen for prostate cancer detection in men (27 vs. 46%, P<0.001).
|
21989122 |
2011 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Survival analysis showed that patients with PSA-producing tumors have a reduced risk for relapse, suggesting PSA to be an independent favorable prognostic marker for a large subset of breast cancer patients.
|
9541191 |
1998 |